EMPagliflozin after Aortic Valve Replacement - the EMPAVR study
Phase 1
Recruiting
- Conditions
- Aortic stenosisMedDRA version: 20.0Level: PTClassification code: 10002916Term: Aortic valve replacement Class: 100000004865MedDRA version: 20.1Level: PTClassification code: 10002906Term: Aortic stenosis Class: 100000004866Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- CTIS2023-504731-40-01
- Lead Sponsor
- Rigshospitalet
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 206
Inclusion Criteria
Severe symptomatic AS AND Surgical or transcatheter AVR within 14 days
Exclusion Criteria
Prior treatment with an SGLT2i, LVEF <45%, eGFR <30ml/min, Hypersensitivity to empagliflozin or placebo tablet
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method